Biotech
Who was here looking at that 80 cent BBI DipBBI is still a long in my opinion. For those of you who don't know, I think the current entry price is still pretty good. Post market recovery, this might start rallying again. Resistance and panic selling already been quite high and the negative positive retracement wedge is likely only to be better given trader's psychology. As always, this is on an opinion based basis. Invest at your own risk and do your own due diligence.
Amgen Just Broke Out. Now it’s Bouncing.Biotechnology has quietly moved up the industry rankings in the last month. We recently highlighted the long-term breakout in the iShares Nasdaq Biotechnology ETF and now its biggest holding (8% of assets) has some interesting patterns: Amgen.
AMGN broke out to new highs in late 2019 and crashed along with the rest of the market in March. It then proceeded to make a higher low in June as it found support at its 200-day simple moving average (SMA). This produced a cup-and-handle chart pattern.
The stock had a tight bullish flag above its 50-day SMA in late June, and then ripped to new highs after winning a patent case against Novartis.
AMGN pulled back last week. It formed a hammer candlestick on Friday and is now bouncing at its 8-day exponential moving average (EMA). That line can serve as a potential risk-management area.
There are two reasons why it may not dip a lot more. First, AMGN hasn’t run much yet versus its December highs. So, there may not be many profit-takers yet. Second, the relative strength in IBB following its recent breakout could provide tailwinds.
AMGN reports earnings after the closing bell on July 28.
ABIO: Currently looking for a Long EntryFirst off, please don't take anything I say as financial advice and as always everything is on an opinion based basis. Pursue your own due diligence. That being said, ABIO seems to have a decent setup for potentially another bull run quite soon. The resistance curve is about to pop and it looks like this is a close watch as with other stocks I been watching. In my opinion the risk isn't too high given the mostly neutral pattern after the bearish action that happened kicking off June. At that point, the risk got mostly reduced and this price for an entry isn't too bad. It still though is risky.
ILLUMINA (ILMN) potential breakout over resistance $372ILMN is one of the highest conviction picks by ARKK investments (ARKK). They invest in disruptive technology that could potentially change the world.
Another pick Invitae(NVTA) has a similar pattern and broke out recently.
Level exhaustion at the $372 level and a potential accumulation zone. A daily close above 372 would be bullish.
An overall bullish sentiment with the price well above the moving averages.
Some key metrics I looked at,
3Y revenue growth: 13.89%
ROIC: 14.22%
P/CF: 48.54
P/S: 15.48
DCF value: $162 (Simply Wall street)
PEG: 2.2X
Future growth: 26.8%
Historical growth: 17.6%
Rule of 40 = net margin + revenue growth = 29+13= 42 (42>40, OK)
Potential tailwinds,
- Leader by market share (More than 90%)
- Relatively new industry
- Covid19 accelerating genome revolution and health trends
- The decline in cost curve
VRCA Bounce Back Swing TradeVRCA has been tanking the last few days due to FDA Approval Delays
Has a history of bouncing around support and resistance levels around this price
Upside is around 80% if positive PR and price action takes place with the weeks
Low Float stock, can be volatile. (Enjoy the ride)
HTGM Patent
$HTGM
has been granted a key Covid-19 patent. The patent relates to a new way of detecting DNA and RNA in the same sample. Exemplary positive-strand RNA viruses include Coronaviruses (examples of which include SARS coronaviruses).
Looking for break of .70c with volume .
PT1 .78c
PT2 .91c
Stop loss set at .5 fib .58c
ArcticZymes is the Covid-19 stock that is valued at 197 mUSDArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate
Tromsø, 02 July, 2020: ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease (SAN-HQ) to be used in the development and manufacturing of ReiThera’s novel vaccine candidate against COVID-19. The vaccine candidate, which is based on ReiThera’s viral vector technology, is scheduled to enter clinical trials soon.
SAN-HQ has established itself within the viral vector-based biopharmaceutical segment, where viruses are used to deliver genetic material into cells to treat or prevent disease. Due to safety concerns, regulators require manufacturers to minimize and control the amount of exogenous nucleic acids impurities (DNA or RNA not encapsulated by the vector) in the final dosage. Therefore, one or more nuclease treatments are often implemented in the downstream processing of the virus, in which the nuclease digests exogenous DNA. Exogenous DNA can also cause the viral particles to aggregate, which reduces both yield and potency of the vector. One of the key strategies to reduce aggregation involves keeping the virus at elevated salt concentrations. Unlike other commercially available nucleases, SAN-HQ digests nucleic acids with high efficiency at high salt concentrations. Furthermore SAN-HQ is utilized at much lower quantities which means less enzyme needs to be removed from the virus following its use which is another key advantage.
To put it into context, the manufacturing process of viral vaccines is a complicated and lengthy multi-stage process with many steps. SAN-HQ is utilised for one part of this process and does not end up as part of the final therapeutic vaccine. Hence, the supply deal relates to the provision of this essential component to streamline part of the process.
ReiThera, together with Leukocare AG (Germany) and Univercells S.A. (Belgium), has formed a pan-European consortium to fast-track the development of its vaccine against the novel coronavirus SARS-CoV-2, which causes COVID-19.
ArcticZymes AS, CEO, Jethro Holter said:
“We are delighted to expand our relationship in supporting ReiThera and its consortium partners with fast tracking its activities to develop a vaccine against the novel coronavirus SARS-CoV-2. ReiThera is a leading European company in genetic vaccine development focused on bringing innovative therapeutics to market via leveraging the best technologies such as ArcticZymes’ SAN-HQ. We look forward to supporting ReiThera in the development and future commercialisation of their vaccine.”
“This agreement seamlessly fits with our efforts to scale up SAN-HQ which is supported by the Innovation Norway funding recently granted to ArcticZymes in May 2020. The timely scaling of SAN-HQ production will satisfy future commercial demand from our partners such as ReiThera.”
ReiThera’s Project Manager, Marco Soriani, said:
“ReiThera’s effort to develop a vaccine against the coronavirus that causes COVID-19 relies on its solid partnerships with key pharmaceutical stakeholders, such as ArcticZymes, which provide crucial technologies to ensure a consistently high-quality product. We look forward to working with ArcticZymes on this important product development program, which aims to tackle the global COVID-19 pandemic.”
-ENDS-
About ReiThera Srl
ReiThera Srl is a biotech company dedicated to the technology development, GMP manufacturing and clinical translation of genetic vaccines and medicinal products for advanced therapies. The company’s management and scientific teams have developed a highly innovative technological platform based on simian adeno-vectored vaccines against several infectious diseases, such as RSV and Ebola. ReiThera is led by an experienced management team that has worked together for many years in previous successful enterprises, including Okairos (acquired by GSK), and has a long-standing expertise in scalable processes for viral vector manufacturing, supported by a cGMP facility inclusive of filling suite and quality control laboratories. ReiThera is also part of a pan-European consortium focused on the development and large-scale manufacture of an adeno-viral vector vaccine against COVID-19.
ReiThera has its headquarters, R&D laboratories and GMP facilities in Rome, Italy.
[NVAX] Novavax: Update - 1.6 billion funded!I still believe NVAX has a lot of potential and I'll say it again. My idea is clear that its NanoParticle and Matrix-M Adjuvant tech makes it a prime candidate for a COVID-19 vaccines. Even if it doesn't make it first (or ever), it still has major potential for the seasonal influenza (w/ NanoFlu) and its Respiratory Syncytial Virus (RSV) vaccine. Check out my original post that is linked.
Today's News:
1. www.cnbc.com
2. www.fool.com
Bullish Charts - Golden Cross, July 6 Conf CallObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. The company is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. It also is developing OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
On 06/29/20, ObsEva announced it will hold a conference call to discuss results from Phase 3 PRIMROSE 1 and PRIMROSE 2 clinical trials evaluating their drug Linzagolix in women with Uterine Fibroids.
I personally think the conference call will be Bullish because on 07/01/20, ObsEva and Yuyuan BioScience Technology announced submission of the PRE-IND Dossier for Nolasiban with Chinese NMPA.
This company has a few things going on that could be a catalyst for the stock moving into July 6, next week.
Daily Chart is Bullish
50-Day MA just crossed up above the 200-Day MA - I believe this cross just happened today on above average volume.
MACD is turning up, Bullish
RSI is Bullish
Stochastic is Bullish
The Cloud indicators are all Bullish as seen below.
8-May-20
3.36 Bullish Kumo Breakout
5-May-20
2.95 Bullish Senkou Span Cross
4-May-20
2.41 Bullish Kijun Sen Cross
29-Apr-20
2.55 Bullish Tenkan/Kijun Cross
20-Apr-20
2.10 Bullish Chikou Span Cross
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
STOCKS TO HEDGE TSLA WITH: MRNA?I like biotech's potential from here and it shows up as a low to medium distance return on TSLA puts in my data experiments
Biotech's Lookin' Good (for a bit at least)Bull flag that looked for a short while like it was pulling a head-fake and retreating but in the last hour of trading (as always) my instincts are rewarded and it continues to climb up. I've put in a prospective overhead resistance but remember to trail your stops because anything can happen! Other ETF's are looking bullish too like DRN, SOXL and TECL.
Long Biotech for Multi-Year CycleIBB looks to have a just broken out of a 5 year basing pattern. The longer the base, the higher in space. I'm going long 3-5 year hold with sell target of >$400.
Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*Link to Culper Research report that states they are shorting VBIV because the company is "worthless"
img1.wsimg.com
First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report.
1) I think many of the points made in the Culper Report are legitimate
2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance
3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data
Stop loss @ $2.04
$AGEN can rise in the next daysContextual immersion trading strategy idea.
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer.
The demand for shares of the company still looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $4,18;
stop-loss — $3,95.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Novavax (NVAX) stock price is on track...for now [LONG]Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one.
This is purely speculation based on their pipeline. This is not financial advice.
Easy - LONG Verastem! Chart, Technicals, Cash, Upcoming news....
These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it.
This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so...
First time we will test with a healthier MACD and CMF on the week....STOCH and RSI look great as well....
not a ton of downside risk - if you want, let go if we break the 200day - but other than that this one is way too easy right now.
ENJOY THE FIRE WORKS <3
$TRVN can rise in the next daysContextual immersion trading strategy idea.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system.
The demand for shares of the company still looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $1,66;
stop-loss — $1,54.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Will LPCN Break back Above Previous Support Or...or will it become resistance? There's been a lot of momentum building up ever since LPCN fell off. We saw some insider buying this month but no new news. Meanwhile other companies are presenting at virtual conferences and all that. It makes you wonder if LPCN has enough steam to reclaim its old levels or if this is just a speculation-driven move in the short term.
"In May Lipocine received RDA clearance for an investigational new drug application for a Phase 2 study of LPCN 1148. This is a prodrug of bioidentical testosterone to treat liver cirrhosis. Furthermore, the company reported results of a preclinical study of its LPCN 1144 which demonstrated encouraging results according to the company. H.C. Wainright took notice of these milestones and increased its price target on LPCN stock to $3 while maintaining a Buy rating."
Quote Source & Info: Can You Make Money With Penny Stocks? 3 Up Big In June
$RETA can rise in the next daysContextual immersion trading strategy idea.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.
The demand for shares of the company still looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $175,59;
stop-loss — $173,13.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
VRTX : SLINGSHOT125% earnings growth past quarter, +30% previous quarters
+76% revenue growth past quarter, accelerating from the precious quarters
Positive earnings revisions
